$139.63
-0.67(-0.48%)
Mkt Cap $173.3B
$96.91
$155.80
52-Week Range
At A Glance
1
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
2
Revenue is primarily driven by Product (33.1%) and HIV Product Sales (23%).
3
Most recently: Entry into a Material Definitive Agreement Agreement and Plan of Merger On February 22, 2026, Gilead Sciences, Inc., a Delaware corporation (“ Parent ” or “ Gil (2026-02-23).
$173.3B
Market Cap
$29.4B
Revenue
$8.5B
Net Income
Employees17,600
Fundamentals
How The Business Makes Money
Revenue by Segment
Product33.1%($168.9B)
HIV Product Sales23%($117.1B)
HIV Products Biktarvy15.5%($79.2B)
Oncology Product3.7%($18.9B)
Liver Disease3.5%($18.0B)
HIV Products Descovy2.7%($13.7B)
Cell Therapy Products Total Cell Therapy Product Sales2.2%($11.4B)
HIV Products Genvoya2.1%($10.6B)
Veklury1.9%($9.8B)
Other Products Yescarta1.8%($9.1B)
Liver Disease Products Sofosbuvir Velpatasvir1.7%($8.8B)
HIV Products Odefsey1.5%($7.6B)
Trodelvy1.5%($7.5B)
Liver Disease Products Vemlidy1.1%($5.8B)
Other Products Total Other Product Sales1%($5.1B)
Liver Disease Products Other Liver Disease0.7%($3.5B)
HIV Products Symtuza Revenue Share0.6%($3.2B)
Other Products Am Bisome0.6%($3.1B)
HIV Products Other HIV0.5%($2.7B)
Cell Therapy Products Tecartus0.4%($2.2B)
Other Products Other0.4%($2.0B)
Royalty Contract And Other0.3%($1.7B)
Revenue by Geography
US71.6%($243.6B)
Europe16.5%($56.2B)
Rest Of World11.9%($40.6B)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0000882095
ISINUS3755581036
CUSIP375558103
Phone650 574 3000
Address333 Lakeside Drive, Foster City, CA, 94404, US
SEC EDGAR